BioSpace News Archive

Genesis Biotechnology Group ® (GBG) and Contract Research Organization (CRO) announced today that it has acquired BioBlocks.

BRIGHT MINDS BIOSCIENCES INC. today announced that Ian McDonald, President & CEO and Josh Blacher, VP of Corporation Development, will present live at VirtualInvestorConferences.com on October 14th.

PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay.

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre

Avinger, Inc. today announced that clinical data from the INSIGHT study were presented during the Late-Breaking Clinical Trials session at the VIVA conference in Las Vegas.

Relay Therapeutics, Inc. today shared preclinical data at the virtual AACR-NCI-EORTC Molecular Targets Conference for RLY-2608, the first allosteric, pan-mutant (H1047X, E542X and E545X) and isoform-selective PI3Kα inhibitor.

ORIC Pharmaceuticals, Inc. today announced multiple presentations, including initial clinical data from an ongoing Phase 1b study evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide.

Helsinn Group, a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, today announces the acceptance of two abstracts on a potent and highly selective RET inhibitor at the AACR-NCI-EORTC Virtual International Conference.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that the Company will present two virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 7-10, 2021.

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, will be presenting design and rationale details of a Phase 1 trial evaluating KIN-2787 during the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.